Zika virus confirmed among 4 Canadian travellers - Action News
Home WebMail Saturday, November 16, 2024, 12:14 AM | Calgary | -0.7°C | Regions Advertise Login | Our platform is in maintenance mode. Some URLs may not be available. |
Health

Zika virus confirmed among 4 Canadian travellers

Zika virus infections have recently been confirmed among four Canadians who have travelled to areas most affected by the virus, the Public Health Agency of Canada says.

Human tests on vaccine could start as early as September, says scientist Gary Kobinger

Zika virus puts countries on edge

8 years ago
Duration 1:50
Canadian health officials share details about research into the fast-spreading virus

Zika virus infections have recently been confirmed among four Canadians who havetravelled to areas most affected by the virus, the Public Health Agency of Canada says.

Two cases in British Columbia, one in Alberta and one in Quebec all resulted from travel to areas where the virus is actively circulating, such asSouth and Central America, and the Caribbean,Dr. Gregory Taylor, Canada's chief public health officer, said Friday.

Dr. Horacio Arruda, Quebec's director of public health, said a woman was infected while travelling to one of the affected areas. She was not pregnant, but showed symptoms and is fine now.

Taylor told a briefing in Ottawa that a consortium of Canadian and U.S. scientists, includingGaryKobinger from the National Microbiology Laboratory in Winnipeg, is working on a potential vaccine.

Taylor saidKobinger will do the vaccine work at Laval University, but it's unclear how the Public Health Agency may be involved in its development.

Developing a vaccine is a priority, Taylor said,because of the association between viral infections in pregnancy and a birth defect calledmicrocephaly abnormally small heads a rareneurological condition that is usually the result of abnormal brain development.

"It's an association that isn't proven yet," Taylor said, adding it's only been observed in a small region of Brazil.

Kobingertold CBC NewsFriday that the vaccine is already in clinical production to use in early stage trials on humans.

"We'll be able to start enrolling volunteers again with [regulatory]approval and start a phase 1 clinical trial in mid or late summer," Kobinger said.

The infection itself is mild, with only 20 to 25 per cent of people developing symptoms such as fever, pink eye, rash and joint ormuscle pain that last for a few days.

Dr. Gregory Taylor, Canada's chief public health officer, says the Zika virus is not a significant risk to Canadians. (Adrian Wyld/Canadian Press)

The virus is transmitted by Aedesmosquitoes that are not well-suited to Canada'sclimate. The risk of infectionsis therefore low in this country.

Dr. Theresa Tam, Canada's deputy chief public health officer, said there issome evidence of mother-to-child transmission.

Federal and provincial health authorities recommendthat pregnant women and those considering becoming pregnant discuss their travel plans with their health-care provider to assess their risk and consider postponing travel to areas where the Zika virus is circulating in the Americas.

Sexual transmission questions

There are also few reports of transmission through infected blood, said Tam. As with many aspects of the illness, more research is needed.

Tam said one published case studydescribed a male traveller to Africa who came back home, andsubsequently his wife developed aZika virus infection without having travelled.

"There has been some detection of the virus in semen for up to two weeks, so until further information is known, that's the fact that we have to work with," Tam said. "Extremely low risk. Precautionary measure might be appropriate."

On Thursday, Canadian Blood Services said it plans to defer blood donations from people who've travelled to the affected areas. Since the virus is found in blood for only a short time, the deferral period is one month, Tam said.

The consortium working on the vaccine includes the University of Pennsylvania, led by scientist David Weiner, theUniversity of Laval, led by Kobinger, Inovio Pharmaceuticals Inc. and South Korea's GeneOne Life Science.